Johnson & Johnson stock steadies as investors weigh Kenvue stake plan and recent earnings
Published on 07/23/2026 at 02:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson stock is underpinned by the healthcare group’s diversified earnings base and portfolio reshaping, with investors weighing the remaining stake in consumer spin-off Kenvue alongside resilient pharmaceuticals and medical technology results disclosed in the latest quarterly filings.
Revenue above 2023 level
According to Johnson & Johnson’s full-year 2023 report, the company generated worldwide sales of roughly $85 billion in 2023, modestly above the prior-year level as growth in innovative medicines and MedTech helped offset the separation of the consumer health business into Kenvue. In that filing, management highlighted that pharmaceuticals remained the largest contributor to group revenue, followed by medical technology, while the consumer health activities were deconsolidated after the spin-off.
The same 2023 disclosure shows that adjusted earnings per share for the year reached a value that was slightly higher than in 2022, indicating that the group maintained profitability despite portfolio changes and litigation expenses related to legacy products. For investors, the comparison with the prior year underscores that Johnson & Johnson’s core businesses continued to grow even as reported sales were affected by the structural shift of moving consumer brands into a separate listed company.
Pharma and MedTech drive growth
In the company’s most recent quarterly results release for 2024, Johnson & Johnson reported that pharmaceutical segment sales increased compared with the corresponding quarter in 2023, supported by key oncology and immunology therapies as well as newer products in the pipeline. The MedTech division also posted year-on-year revenue growth in that quarter, helped by procedure volume recovery and demand for devices and surgical technologies, partially offset by pricing pressure in some categories.
The management team reiterated in that 2024 quarterly update that it is focusing capital allocation on higher-growth and higher-margin areas, including expanding indications for existing drugs and investing in MedTech innovation, while optimizing the portfolio after the Kenvue separation. The combination of mid-single-digit revenue growth in the latest quarter and stable adjusted margins suggests that Johnson & Johnson is aiming to generate steady earnings progression even as it faces patent expirations and competitive pressures.
Johnson & Johnson fundamentals in focus
For more background on Johnson & Johnson’s latest filings and corporate actions, including detailed segment performance, visit the company topic page and the group’s Investor Relations site.
Kenvue stake and capital allocation
Johnson & Johnson continues to hold a minority stake in Kenvue, the consumer health company it spun off, and has signaled in filings that it intends to exit this position over time as market conditions and capital priorities allow. The spin-off simplified the group’s structure, leaving Johnson & Johnson focused on pharmaceuticals and MedTech, while the Kenvue shares provide an additional source of financial flexibility through potential future disposals.
The company has also emphasized in recent communications that it is committed to returning cash to shareholders through dividends and share repurchases, subject to its balance sheet and investment needs. Johnson & Johnson has a long record of annual dividend increases, and maintaining this track record remains an important part of its equity story for income-oriented investors alongside the potential value realization from monetizing the remaining Kenvue stake.
Key products support Johnson & Johnson stock
Among Johnson & Johnson’s key pharmaceuticals, oncology and immunology therapies have been central to recent revenue growth, with management pointing to increased volumes and expanded indications in its 2023 and 2024 updates. In MedTech, the company has highlighted advanced surgical technologies and orthopedic products as drivers of higher procedure-related sales, as hospitals and clinics continue to normalize activity levels compared with earlier in the decade.
These products, together with a research and development pipeline focused on areas such as oncology, neuroscience, and cardiovascular disease, help underpin expectations for medium-term growth beyond current patent cycles. For Johnson & Johnson stock, the balance between proven blockbuster products and late-stage pipeline candidates is a key factor investors monitor when assessing the company’s valuation relative to other global healthcare groups.
Johnson & Johnson stock and market context
Johnson & Johnson shares trade on the New York Stock Exchange under the ticker JNJ, and the company is a component of major indices such as the Dow Jones Industrial Average and the S&P 500. The group’s large market capitalization and diversified business profile mean that Johnson & Johnson stock is often viewed as a defensive holding within healthcare, with earnings and dividends that tend to be less cyclical than those of many other sectors.
Against this backdrop, the interaction between earnings growth, litigation developments, and the gradual exit from the Kenvue stake will likely continue to shape how Johnson & Johnson stock trades relative to the broader market and to other large-cap healthcare peers. For long-term investors, the central questions remain the pace of growth in pharmaceuticals and MedTech, the durability of key product franchises, and the company’s ability to sustain its dividend and balance sheet strength while investing in innovation.
Johnson & Johnson stock snapshot
- Company: Johnson & Johnson
- ISIN: US4781601046
- Ticker: NYSE: JNJ
- Trading venue: NYSE
- Sector / Industry: Health Care / Pharmaceuticals, Biotechnology and Life Sciences
- Index membership: Dow Jones Industrial Average, S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
